JP2022537269A5 - - Google Patents
Info
- Publication number
- JP2022537269A5 JP2022537269A5 JP2021573213A JP2021573213A JP2022537269A5 JP 2022537269 A5 JP2022537269 A5 JP 2022537269A5 JP 2021573213 A JP2021573213 A JP 2021573213A JP 2021573213 A JP2021573213 A JP 2021573213A JP 2022537269 A5 JP2022537269 A5 JP 2022537269A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- muc16
- cancer
- agonist
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024144172A JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864960P | 2019-06-21 | 2019-06-21 | |
| US62/864,960 | 2019-06-21 | ||
| PCT/US2020/038669 WO2020257604A1 (en) | 2019-06-21 | 2020-06-19 | Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144172A Division JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537269A JP2022537269A (ja) | 2022-08-25 |
| JP2022537269A5 true JP2022537269A5 (cg-RX-API-DMAC10.html) | 2023-06-20 |
| JP7743314B2 JP7743314B2 (ja) | 2025-09-24 |
Family
ID=71842848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573213A Active JP7743314B2 (ja) | 2019-06-21 | 2020-06-19 | Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
| JP2024144172A Pending JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144172A Pending JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12091460B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3986934A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7743314B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220024035A (cg-RX-API-DMAC10.html) |
| CN (2) | CN118453851A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020294790A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3140083A1 (cg-RX-API-DMAC10.html) |
| IL (2) | IL288916B2 (cg-RX-API-DMAC10.html) |
| MA (1) | MA56537A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2021015270A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020257604A1 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA202108895B (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102531251B1 (ko) * | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| EP4308160A4 (en) * | 2021-03-18 | 2025-07-02 | Memorial Sloan Kettering Cancer Center | METHODS OF TREATING GYNECOLOGICAL CANCER USING COMBINATION THERAPY WITH MULTISPECIFIC ANTI-MUC16 X CD3 ANTIBODIES AND VEGF INHIBITORS |
| IL315405A (en) * | 2022-03-17 | 2024-11-01 | Regeneron Pharma | Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies |
| JP2025529310A (ja) * | 2022-09-06 | 2025-09-04 | ティージェイ バイオファーマ (シャンハイ) カンパニー, リミテッド | 多特異性構築物およびその使用 |
| WO2025082777A1 (en) * | 2023-10-17 | 2025-04-24 | Morphosys Ag | Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| TW202542187A (zh) * | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
| US11033642B2 (en) | 2014-03-19 | 2021-06-15 | Universitat Zurich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
| CA2949936C (en) * | 2014-06-10 | 2022-10-18 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| NZ731966A (en) * | 2014-10-16 | 2019-11-29 | Univ Melbourne | Novel imaging composition and uses thereof |
| KR102618312B1 (ko) | 2015-03-17 | 2023-12-28 | 메모리얼 슬로안 케터링 캔서 센터 | 항muc16 항체 및 그의 용도 |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| MY195059A (en) * | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| KR102531251B1 (ko) * | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| RS67792B1 (sr) * | 2016-12-01 | 2026-03-31 | Regeneron Pharma | Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje |
| JP7125400B2 (ja) | 2016-12-19 | 2022-08-24 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 標的化4-1bb(cd137)アゴニストとの併用療法 |
| KR102692708B1 (ko) * | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
-
2020
- 2020-06-19 JP JP2021573213A patent/JP7743314B2/ja active Active
- 2020-06-19 KR KR1020217040895A patent/KR20220024035A/ko not_active Ceased
- 2020-06-19 MA MA056537A patent/MA56537A/fr unknown
- 2020-06-19 WO PCT/US2020/038669 patent/WO2020257604A1/en not_active Ceased
- 2020-06-19 MX MX2021015270A patent/MX2021015270A/es unknown
- 2020-06-19 IL IL288916A patent/IL288916B2/en unknown
- 2020-06-19 EP EP20747267.1A patent/EP3986934A1/en active Pending
- 2020-06-19 CN CN202410406230.1A patent/CN118453851A/zh active Pending
- 2020-06-19 CN CN202080045426.2A patent/CN113993547B/zh active Active
- 2020-06-19 AU AU2020294790A patent/AU2020294790A1/en active Pending
- 2020-06-19 US US16/906,634 patent/US12091460B2/en active Active
- 2020-06-19 CA CA3140083A patent/CA3140083A1/en active Pending
-
2021
- 2021-11-10 ZA ZA2021/08895A patent/ZA202108895B/en unknown
-
2024
- 2024-08-19 US US18/809,063 patent/US20250042999A1/en active Pending
- 2024-08-26 JP JP2024144172A patent/JP2024164188A/ja active Pending
-
2025
- 2025-10-09 IL IL323844A patent/IL323844A/en unknown